Sidewinder Therapeutics Funding: $162M Raised, Series B
Sidewinder Therapeutics is based in San Diego. It has raised $162M in total funding. Latest round: Series B.
Sidewinder Therapeutics funding overview
Sidewinder Therapeutics is based in San Diego. Sidewinder Therapeutics has raised $162M in total disclosed funding. That places its disclosed total in the $100M–$250M range. Its most recent disclosed round is a Series B announced in April 2026. The round record for Sidewinder Therapeutics runs through 2026; nothing later has been disclosed. Investors on record include Frazier Life Sciences, Novartis Venture Fund, OrbiMed, Life Sciences at Goldman Sachs Alternatives, DCVC Bio, Samsara BioCapital and 3 others. 9 distinct backers are named across the disclosed rounds.
Sidewinder Therapeutics at a glance
Total raised
$162M
Latest round
Series B
Latest round date
April 2026
Headquarters
San Diego
Notable investors
Frazier Life Sciences, Novartis Venture Fund, OrbiMed, Life Sciences at Goldman Sachs Alternatives, DCVC Bio, Samsara BioCapital, Longwood Fund, Astellas Venture Management
Frequently asked about Sidewinder Therapeutics funding
How much has Sidewinder Therapeutics raised?
Sidewinder Therapeutics has raised $162M in total disclosed funding across the rounds on record.
Who has invested in Sidewinder Therapeutics?
Frazier Life Sciences, Novartis Venture Fund, OrbiMed, Life Sciences at Goldman Sachs Alternatives, DCVC Bio, Samsara BioCapital are named among the investors backing Sidewinder Therapeutics.
What was the latest Sidewinder Therapeutics funding round?
The most recent disclosed round is a Series B, announced in April 2026.
Where is Sidewinder Therapeutics based?
Sidewinder Therapeutics is based in San Diego.
When did Sidewinder Therapeutics last raise?
The last disclosed Sidewinder Therapeutics round closed in April 2026 at Series B.
Sidewinder Therapeutics totals reflect disclosed capital only — undisclosed extensions and secondaries are excluded. Use the related companies in San Diego below to benchmark round size and investor mix.
